These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30917125)

  • 21. Hepcidin/Ferritin Ratios Differ Among Non-Dialyzed Chronic Kidney Disease Patients, and Patients on Hemodialysis and Peritoneal Dialysis.
    Niikura T; Maruyama Y; Nakashima S; Matsuo N; Tanno Y; Ohkido I; Yokoyama K; Yamamoto H; Yokoo T
    Ther Apher Dial; 2019 Aug; 23(4):341-346. PubMed ID: 30411489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers.
    Cheng YF; Jiang J; Hu P; Reinholdsson I; Guo W; Asenblad N; Nilsson D
    Clin Ther; 2008 Dec; 30(12):2342-53. PubMed ID: 19167593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.
    Lim JJ; Deng R; Derby MA; Larouche R; Horn P; Anderson M; Maia M; Carrier S; Pelletier I; Burgess T; Kulkarni P; Newton E; Tavel JA
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5437-44. PubMed ID: 27381392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
    Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
    Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: a randomized controlled trial.
    Panwar B; McCann D; Olbina G; Westerman M; Gutiérrez OM
    BMC Nephrol; 2018 Feb; 19(1):35. PubMed ID: 29426300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers.
    Li X; Li B; Wang M; Fang M; Lou J; Liu J; Chen H; Ding Y
    BioDrugs; 2024 Mar; 38(2):313-321. PubMed ID: 38148466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum Hepcidin and Iron Indices Affect Anemia Status Differently According to the Kidney Function of Non-Dialysis Chronic Kidney Disease Patients: Korean Cohort Study For Outcome in Patients with Chronic Kidney Disease (KNOW-CKD).
    Lee SW; Kim YH; Chung W; Park SK; Chae DW; Ahn C; Kim YS; Sung SA
    Kidney Blood Press Res; 2017; 42(6):1183-1192. PubMed ID: 29227972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
    Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
    Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
    Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
    Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
    Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
    J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency.
    Brătescu LO; Bârsan L; Gârneaţă L; Stanciu A; Lipan M; Stancu SH; Mircescu G
    Int Urol Nephrol; 2014 May; 46(5):1005-12. PubMed ID: 24800994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau.
    Luca W; Foster K; McClure K; Ahlijanian MK; Jefson M
    J Prev Alzheimers Dis; 2024; 11(2):366-374. PubMed ID: 38374743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study.
    Whittaker A; Kragh ÅM; Hartleib-Geschwindner J; Albayaty M; Backlund A; Greasley PJ; Heijer M; Kjaer M; Forte P; Unwin R; Wernevik L; Ericsson H
    Clin Transl Sci; 2020 Mar; 13(2):275-283. PubMed ID: 31584739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
    Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T
    Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepcidin and proinflammatory markers in children with chronic kidney disease: A case-control study
.
    Goyal KK; Saha A; Sahi PK; Kaur M; Dubey NK; Goyal P; Upadhayay AD
    Clin Nephrol; 2018 May; 89(5):363-370. PubMed ID: 29451472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects.
    Hussaini A; Mukherjee R; Berdieva DM; Glogowski C; Mountfield R; Ho PTC
    Clin Transl Sci; 2020 Mar; 13(2):337-344. PubMed ID: 31664766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Curcuma decreases serum hepcidin levels in healthy volunteers: a placebo-controlled, randomized, double-blind, cross-over study.
    Lainé F; Laviolle B; Bardou-Jacquet E; Fatih N; Jezequel C; Collet N; Ropert M; Morcet J; Hamon C; Reymann JM; Loréal O
    Fundam Clin Pharmacol; 2017 Oct; 31(5):567-573. PubMed ID: 28370178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
    Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
    Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.